Broad Plans Large Sequencing Study to ID Personalized Drug Candidates for Psychiatric Disorders | GenomeWeb

Originally published July 28.

NEW YORK (GenomeWeb) – After announcing that it has been promised $650 million in support from philanthropist Ted Stanley, the Broad Institute's Stanley Center is now planning a large-scale sequencing study to attempt to identify new molecular drug targets in psychiatric disorders and begin screening compounds that could be developed into personalized therapies for these diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.